|
Delayed
Canadian Securities Exchange
15:21:54 2026-08-26 EDT
|
5-day change | 1st Jan Change | ||
| 0.005000 CAD | -50.00% |
|
-.--% | -91.67% |
| Market Cap | 597K 431K 371K 349K 319K 40.74M 599K 4.13M 1.6M 20.9M 1.62M 1.58M 67.33M | P/E 2024 |
-0.07x | P/E 2025 | -0.2x |
|---|---|---|---|---|---|
| Enterprise Value | -127K -91.46K -78.7K -74.05K -67.64K -8.64M -127K -875K -340K -4.43M -343K -336K -14.27M | EV / Sales 2024 |
0.13x | EV / Sales 2025 | 0.32x |
| Free-Float |
68.57% | Yield 2024 * |
-
| Yield 2025 | - |
| 1 day | -50.00% | ||
| 1 month | -50.00% | ||
| 3 months | -66.67% | ||
| 6 months | -75.00% | ||
| Current year | -91.67% |
| 1 month | 0 | 0.01 | |
| Current year | 0 | 0.05 | |
| 1 year | 0 | 0.25 | |
| 3 years | 0 | 0.25 | |
| 5 years | 0 | 0.6 | |
| 10 years | 0 | 1.19 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jackie Burnett
CEO | Chief Executive Officer | - | 2019-09-30 |
José Roldan
DFI | Director of Finance/CFO | - | 2022-12-08 |
| Director | Title | Age | Since |
|---|---|---|---|
Jackie Burnett
BRD | Director/Board Member | - | 2019-09-30 |
Daniel Augereau
BRD | Director/Board Member | 82 | 2019-09-30 |
Eric Klein
BRD | Director/Board Member | 66 | 2019-09-30 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 6/2/25 | Sell | Chief Executive Officer | 4,667,000 | 3.9091% | ||
| 3/21/25 | Buy | Chief Executive Officer | 200,000 | 0.1675% | ||
| 3/21/25 | Buy | Chief Executive Officer | 100,000 | 0.0838% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -50.00% | -.--% | -50.00% | -90.00% | 431K | ||
| -0.88% | -2.15% | +58.05% | +105.26% | 1,024B | ||
| -1.15% | +2.68% | +54.25% | +74.19% | 663B | ||
| -1.44% | +0.38% | +20.65% | +76.13% | 453B | ||
| -0.67% | +0.37% | +31.10% | +37.97% | 352B | ||
| -2.74% | +2.39% | +23.34% | +42.39% | 304B | ||
| +0.61% | +0.90% | +0.84% | +11.51% | 252B | ||
| -1.55% | +1.11% | +54.15% | +75.59% | 236B | ||
| -0.21% | +2.00% | -14.04% | -55.90% | 206B | ||
| -0.15% | +3.65% | +31.24% | +103.39% | 187B | ||
| Average | -5.82% | +1.14% | +20.96% | +38.05% | 367.84B | |
| Weighted average by Cap. | -1.00% | +0.62% | +37.75% | +67.00% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 4.34M 3.14M 2.7M 2.54M 2.32M 296M 4.35M 30.02M 11.65M 152M 11.78M 11.53M 490M | 3.36M 2.43M 2.09M 1.97M 1.8M 229M 3.37M 23.24M 9.02M 118M 9.12M 8.92M 379M |
| Net income | -16.5M -11.93M -10.26M -9.66M -8.82M -1.13B -16.55M -114M -44.28M -578M -44.79M -43.81M -1.86B | -8.91M -6.44M -5.54M -5.21M -4.76M -608M -8.93M -61.61M -23.91M -312M -24.18M -23.66M -1.01B |
| Net Debt | -626K -452K -389K -366K -334K -42.7M -627K -4.33M -1.68M -21.91M -1.7M -1.66M -70.58M | -723K -523K -450K -423K -387K -49.37M -725K -5M -1.94M -25.33M -1.96M -1.92M -81.61M |
Employees
-
Sector
Pharmaceuticals
- Stock Market
- Stocks
- RAMM Stock
Select your edition
All financial news and data tailored to specific country editions
















